Condition: Prolactinoma · Prolactin Excess · Sponsor: University of Sao Paulo General Hospital
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve. The sample will be added consecutively and randomized into 2 unblinded groups: the high dosage group will receive a high cabergoline (CAB) dose for a period of \~6 months vs the standard dosage group, which will use the lowest needed dose of CAB to achieve normoprolactinemia for 2 years. The primary outcome will be remission rate.
This description comes directly from the study's public registry record.
Andrea Glezer, MD, PhD · 55 11 995791108 · andrea.glezer@hc.fm.usp.br
Always discuss trial participation with your own doctor first.
| UFMG | Belo Horizonte, Brazil | Recruiting |
| Unesp | Botucatu, Brazil | Recruiting |
| UNB | Brasília, Brazil | Recruiting |
| Unicamp | Campinas, Brazil | Recruiting |
| UFPR | Curitiba, Brazil | Recruiting |
| UFG | Goiânia, Brazil | Recruiting |
| CPC | Ponta Grossa, Brazil | Recruiting |
| HCPA | Porto Alegre, Brazil | Completed |
| Hospital Moinhos de Vento | Porto Alegre, Brazil | Recruiting |
| Sta Casa-RS | Porto Alegre, Brazil | Recruiting |
| UFPE | Recife, Brazil | Recruiting |
| USP-RP | Ribeirão Preto, Brazil | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07463235